 

Active Ingredient: Betamethasone valerate 

 

Dosage Form; Route: Lotion; topical 

 

Recommended Studies: Two studies 

 

 

1. Type of study: Pilot vasoconstrictor study 


Design: A pilot dose duration-response study using the reference product 

Strength: 0.1% (as betamethasone) 

Subjects: Healthy males and nonpregnant, nonlactating females, general population 

Additional Comments: Please refer to the guidance “Topical Dermatological 
Corticosteroids: In Vivo Bioequivalence” available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070234.pdf. 

 

2. Type of study: Pivotal vasoconstrictor study 


Design: A pivotal bioequivalence study 

Strength: 0.1% (as betamethasone) 

Subjects: Healthy males and nonpregnant, nonlactating females, general population 

Additional Comments: Please refer to the guidance above 

 

 

Analytes to measure (in appropriate biological fluid): N/A 

Bioequivalence based on (90% CI): Pivotal vasoconstrictor study 

Waiver request of in vivo testing: N/A 

Dissolution test method and sample times: N/A 

 


